$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

2 weeks ago 8

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 12:56 PM CST 4 min read

Perceptive Advisors disclosed a merchantability of 1,002,282 Arcellx (NASDAQ:ACLX) shares successful a February 17, 2026, SEC filing, with the estimated transaction worth astatine $79.96 cardinal based connected quarterly mean pricing.

According to a SEC filing dated February 17, 2026, Perceptive Advisors reduced its Arcellx holdings by 1,002,282 shares during the 4th quarter. The estimated worth of these stock income is $79.96 million, based connected the mean unadjusted closing terms for the quarter. The quarter-end worth of the Arcellx presumption declined by $107.06 million, a fig that includes some stock simplification and stock terms movements.

Top holdings aft the filing:
- NASDAQ:PRAX: $588.30 cardinal (10.8% of AUM)
- NASDAQ:CELC: $315.20 cardinal (5.8% of AUM)
- NASDAQ:RYTM: $272.57 cardinal (5.0% of AUM)
- NASDAQ:ASND: $230.60 cardinal (4.2% of AUM)
- NASDAQ:APGE: $175.92 cardinal (3.2% of AUM)
As of February 17, 2026, Arcellx shares were priced astatine $70.20, up 9.2% implicit the past twelvemonth and underperforming the S&P 500 by 4.3 percent points.

Metric

Value

Price (as of marketplace adjacent 2/17/26)	$70.20
Market capitalization	$4.06 billion
Revenue (TTM)	$35.90 million
Net income (TTM)	($217.90 million)

Arcellx develops immunotherapies, with a superior absorption connected CART-ddBCMA for relapsed oregon refractory aggregate myeloma, and further pipeline candidates targeting acute myeloid leukemia, myelodysplastic syndrome, and coagulated tumors.
Arcellx operates arsenic a clinical-stage biotechnology company.

Arcellx is simply a clinical-stage biotechnology institution leveraging proprietary compartment therapy platforms to code unmet aesculapian needs successful oncology. With a specialized pipeline targeting aggregate myeloma and hematologic malignancies, the institution positions itself astatine the forefront of next-generation immunotherapies. Its strategical absorption connected innovative merchandise candidates and collaborative partnerships underpins its competitory vantage successful the biotechnology sector.

This determination comes arsenic Arcellx is nary longer conscionable competing against different approved CAR-Ts. It is defending its aboriginal against a caller transportation model.

In November, Kelonia’s three-patient information acceptable was capable to nonstop Arcellx down astir 17% successful a azygous session. The successful vivo CAR-T attack could theoretically destruct apheresis, ex vivo manufacturing, and lymphodepletion. That is disruptive connection successful a abstraction built connected analyzable logistics. But the follow-up was conscionable 3 months, and the champion reported effect was a precise bully partial response. Though shares person yet to recover, analysts astatine Guggenheim and Citi some argued the sell-off was overdone.

Arcellx’s anito-cel is already successful Phase 3 for relapsed oregon refractory aggregate myeloma successful concern with Gilead’s Kite unit, putting it successful a acold much precocious presumption than aboriginal proof-of-concept data. Shares are up astir 9% implicit the past twelvemonth but person fallen sharply since November, underscoring however sentiment tin flip rapidly successful biotech.

For semipermanent investors, this is astir probability and positioning. Advanced objective assets with established partners thin to transportation antithetic hazard profiles than level concepts successful 3 patients. Volatility is portion of the model. The question is whether anito-cel’s durability tin clasp its crushed arsenic the subject evolves.

Read Entire Article